BioSynova is the AI clinical intelligence company built to scale what oncology and hematology have always run on and never been able to extend: expert specialist judgment.

Specialist reasoning does not scale. There are not enough oncologists and hematologists to follow every patient who needs longitudinal oversight, and the systems built to extend specialist capacity were designed for the acute moment, not the continuous interpretation that cancer risk, blood health, and survivorship demand. The technology to read biological signals earlier than ever now exists. The infrastructure to act on it at scale does not.

We are building that infrastructure. Agentic AI systems, proprietary clinical decision support, and a governed longitudinal data architecture that extend specialist reasoning across the full arc of care, with the physician at the center of every decision. The technology runs on the backend. The judgment stays human.

BioSynova holds the intellectual property, the technology stack, and the operational frameworks that power BioNurture today and are built to scale across markets nationally. BioNurture is the clinical proof point. BioSynova is the layer underneath it, designed to extend the reach of expert physician judgment far beyond what any single practice can hold.

This is hard problem space. Molecular science, machine learning, and care delivery, converging on one conviction: AI in oncology should augment clinical judgment, reduce fragmentation, and return time and clarity to patients and physicians alike. We are building for the engineers and clinicians who want to work where that convergence actually happens.

The next era of cancer care will not be defined by a better hospital. It will be defined by the intelligence layer between patients and a system built only for the acute moment, one that catches earlier, coordinates deeper, and follows longer than any episodic model can.

Biosynova

Org chart

Teams

Offices

Biosynova

Org chart

Teams

Offices

Related companies